Prof Andrew Spencer presents KappaMab Phase 2b interim analysis results at ASH 2019
On Dec 7-10, 2019, Professor Andrew Spencer from Alfred Health in Melbourne presented the interim results from the Phase 2b clinical trial on KappaMab at the 61st annual ASH meeting in Orlando, Florida. This clinical trial is evaluating KappaMab antibody alone and a combination of KappaMab plus lenalidomide and low-dose dexamethasone. Twenty-one of a planned 40 patients had commenced treatment in the combination arm at the time of the presentation. The combination therapy has been well tolerated. The study is ongoing.